These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 19302802)

  • 1. Treatment with a p38 MAPK inhibitor attenuates cisplatin nephrotoxicity starting after the beginning of renal damage.
    Francescato HD; Costa RS; da Silva CG; Coimbra TM
    Life Sci; 2009 Apr; 84(17-18):590-7. PubMed ID: 19302802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with a p38 MAPK inhibitor attenuates cisplatin nephrotoxicity starting after the beginning of renal damage.
    Francescato HD; Costa RS; Silva CG; Coimbra TM
    Life Sci; 2009 Apr; 84(17-18):590-7. PubMed ID: 26324989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parthenolide reduces cisplatin-induced renal damage.
    Francescato HD; Costa RS; Scavone C; Coimbra TM
    Toxicology; 2007 Jan; 230(1):64-75. PubMed ID: 17156909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of JNK inhibition on cisplatin-induced renal damage.
    Francescato HD; Costa RS; Júnior FB; Coimbra TM
    Nephrol Dial Transplant; 2007 Aug; 22(8):2138-48. PubMed ID: 17438009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice.
    Ramesh G; Reeves WB
    Am J Physiol Renal Physiol; 2005 Jul; 289(1):F166-74. PubMed ID: 15701814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of p38 MAPK improves intestinal disturbances and oxidative stress induced in a rabbit endotoxemia model.
    Gonzalo S; Grasa L; Arruebo MP; Plaza MA; Murillo MD
    Neurogastroenterol Motil; 2010 May; 22(5):564-72, e123. PubMed ID: 20003078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxytocin inhibits NADPH oxidase and P38 MAPK in cisplatin-induced nephrotoxicity.
    Rashed LA; Hashem RM; Soliman HM
    Biomed Pharmacother; 2011 Oct; 65(7):474-80. PubMed ID: 21993003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of p38 MAPK activation attenuates esophageal mucosal damage in a chronic model of reflux esophagitis.
    Zhang L; Liu G; Han X; Liu J; Li GX; Zou DW; Li ZS
    Neurogastroenterol Motil; 2015 Nov; 27(11):1648-56. PubMed ID: 26353842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p38 MAPK Inhibitor Insufficiently Attenuates HSC Senescence Administered Long-Term after 6 Gy Total Body Irradiation in Mice.
    Lu L; Wang YY; Zhang JL; Li DG; Meng AM
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of p38-MAPK potentiates cisplatin-induced apoptosis via GSH depletion and increases intracellular drug accumulation in growth-arrested kidney tubular epithelial cells.
    Rodríguez-García ME; Quiroga AG; Castro J; Ortiz A; Aller P; Mata F
    Toxicol Sci; 2009 Oct; 111(2):413-23. PubMed ID: 19578154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-1 beta induction of neuron apoptosis depends on p38 mitogen-activated protein kinase activity after spinal cord injury.
    Wang XJ; Kong KM; Qi WL; Ye WL; Song PS
    Acta Pharmacol Sin; 2005 Aug; 26(8):934-42. PubMed ID: 16038625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A p38 mitogen-activated protein kinase inhibitor attenuates cardiotonic steroids-induced apoptotic and stress signaling in a Sw-71 cytotrophoblast cell line.
    Ehrig JC; Afroze SH; Reyes M; Allen SR; Drever NS; Pilkinton KA; Kuehl TJ; Uddin MN
    Placenta; 2015 Nov; 36(11):1276-82. PubMed ID: 26360379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of p38 mitogen-activated protein kinase pathway ameliorates delayed intestinal transit in burned rats.
    Gan HT; Pasricha PJ; Chen JD
    Am J Surg; 2007 Apr; 193(4):530-7. PubMed ID: 17368305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of phorbol ester-induced regulation of matrix metalloproteinases and tissue inhibitors of metalloproteinases by SB203580, a specific inhibitor of p38 mitogen-activated protein kinase.
    Park MJ; Park IC; Hur JH; Kim MS; Lee HC; Woo SH; Lee KH; Rhee CH; Hong SI; Lee SH
    J Neurosurg; 2002 Jul; 97(1):112-8. PubMed ID: 12134900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effects of p38 mitogen activated protein kinase inhibitor SB203580 on colonic mucosa tumor necrosis factor alpha expression in ulcerative colitis].
    Yi WQ; Gan HT; Huang XL; Zhang M; Ouyang Q
    Zhonghua Nei Ke Za Zhi; 2007 Sep; 46(9):747-50. PubMed ID: 18028805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p38 mitogen-activated protein kinase inhibition decreases TNFalpha secretion and protects against left ventricular remodeling in rats with myocardial ischemia.
    Yin H; Zhang J; Lin H; Wang R; Qiao Y; Wang B; Liu F
    Inflammation; 2008 Apr; 31(2):65-73. PubMed ID: 17943427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p38 mitogen-activated protein kinase contributes to cell cycle regulation by cAMP in FRTL-5 thyroid cells.
    Corrèze C; Blondeau JP; Pomérance M
    Eur J Endocrinol; 2005 Jul; 153(1):123-33. PubMed ID: 15994754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of SB203580, a p38 MAPK Inhibitor, Reduced the Expression of MMP9, and Relieved Neurologic Severity in the Experimental Autoimmune Neuritis (EAN) in Rats.
    Sun Y; Chen H; Ma S; Liang L; Zheng Y; Guo X; Wang M; Wang W; Li G; Zhong D
    Neurochem Res; 2015 Jul; 40(7):1410-20. PubMed ID: 25998885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnesium depletion enhances cisplatin-induced nephrotoxicity.
    Lajer H; Kristensen M; Hansen HH; Nielsen S; Frøkiaer J; Ostergaard LF; Christensen S; Daugaard G; Jonassen TE
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):535-42. PubMed ID: 15947931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal tight junction proteins are decreased in cisplatin-induced nephrotoxicity in rats.
    Trujillo J; Molina-Jijón E; Medina-Campos ON; Rodríguez-Muñoz R; Reyes JL; Loredo ML; Tapia E; Sánchez-Lozada LG; Barrera-Oviedo D; Pedraza-Chaverri J
    Toxicol Mech Methods; 2014 Oct; 24(7):520-8. PubMed ID: 25052570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.